Drugs / Branebrutinib
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05303220 | Apr → Aug 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04515628 | Aug → Oct 2020 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03262740 | Sep → Dec 2017 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03245515 | Aug → Sep 2017 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03131973 | May → Nov 2017 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02705989 | Aug 2016 → Aug 2017 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT05014438 | Aug 2021 → Aug 2022 | atopic eczema | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT04186871 | Jan 2020 → Dec 2022 | Sjogren syndrome, rheumatoid arthritis, systemic lupus erythematosus | Bristol-Myers Squibb | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | branebrutinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04186871 ↗ |
| Known as | BMS-986195 | “Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised,...” PMID 42081904 ↗ May 2026 |
| Action | Inhibit | “irreversible Bruton's tyrosine kinase inhibitor” PMID 42081904 ↗ May 2026 |
| Modality | Small molecule | — CHEMBL4297674 ↗ |
| Route | Oral | “single and multiple ascending oral doses of BMS-986195” NCT02705989 ↗ |
| Target | BTK | “irreversible Bruton's tyrosine kinase inhibitor” PMID 42081904 ↗ May 2026 |